The scope of the global Pharmacogenomics Technology (Theranostics and Companion Diagnostics) Market was appreciated by US$ 5.62 billion in 2016 and it is likely to reach US$ 18.3 billion during the forecast period. This could be attributed to growth in geriatric population, prevalence of chronic diseases like HIV, tuberculosis, and cancer, increase in awareness amongst the patients regarding personalized therapy, and adoption of pharmacogenomics by loads of healthcare professionals.
The pharmacogenomics technology market is also likely to get bolstered technological advancements related to molecular diagnostics. At the same time, there is a dearth on the part of highly skilled and trained healthcare professionals in conducting pharmacogenomics diagnostics tests. Besides, emerging economies need to think twice before affirming pharmacogenomics tests as initial as well as operating costs are high. Governments herein do struggle with funding on this count.
Request a Free Sample Copy @ https://www.millioninsights.com/industry-reports/pharmacogenomics-technology-market/request-sample
Market Segmentation:
The pharmacogenomics theranostics market is segmented by application, technology, end-user, and geography. By application, the segmentation goes like cardiovascular disease, pain management, psychiatry, infectious diseases, oncology, and neurological disease. By technology, the pharmacogenomics technology industry spans sequencing, polymerase chain reaction, mass spectrometry, microarray, and electrophoresis. By end-user, the pharmacogenomics companion diagnostics (CDx) market states research organizations & academic institutes and hospitals and clinics. By geography, it comprises North America, Asia Pacific, LATAM, Europe, and MEA.
Regional Insights:
North America rules the roost; thanks to extensive investment in healthcare by the U.S. Europe comes in second due to Belgium and Denmark being on the top pedestal with respect to healthcare. Asia Pacific is expected to grow at the fastest pace owing to increase in awareness among the economies like India and China regarding healthcare. LATAM will also catch up due to presence of Brazil; followed by MEA. In fact, MEA would be more vigilant on this count; due to the figures released by WHO. It says that over 50% of the diseases mentioned above occur in sub-Saharan Africa.
Players:
The players contributing to the pharmacogenomics technology market include OPKO Health, Inc., Thermo Fisher Scientific, Inc., Teva Pharmaceutical Industries Ltd., Dynamic DNA Laboratories, Abbott Laboratories, F. Hoffmann-La Roche Ltd., One Ome LLC, Empire Genomics, LLC, and Illumina, Inc.
Browse Report Summary with TOC @ https://www.millioninsights.com/industry-reports/pharmacogenomics-technology-market
Market Segment:
Therapeutic Area Outlook (Revenue, USD Million; 2014 - 2025)
• Oncology
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Others
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Others
Technology Outlook (Revenue, USD Million; 2014 - 2025)
• PCR
• In-situ Hybridization
• Immunohistochemistry
• Sequencing
• Others
Regional Outlook (Revenue, USD Million; 2014 - 2025)
• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• Asia Pacific
• China
• Japan
• Latin America
• Brazil
• Middle East & Africa
• South Africa
Find More Category Reports @ https://www.millioninsights.com/industry/healthcare
Get in touch
At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.
Contact Person:
Ryan Manuel
Research Support Specialist, USA
Email: [email protected]
Million Insights
Office No. 302, 3rd Floor, Manikchand Galleria,
Model Colony, Shivaji Nagar, Pune, MH, 411016 India
Phone: 91-20-65300184
Email: [email protected]
The scope of the global Pharmacogenomics Technology (Theranostics and Companion Diagnostics) Market was appreciated by US$ 5.62 billion in 2016 and it is likely to reach US$ 18.3 billion during the forecast period.
This could be attributed to growth in geriatric population, prevalence of chronic diseases like HIV, tuberculosis, and cancer, increase in awareness amongst the patients regarding personalized therapy, and adoption of pharmacogenomics by loads of healthcare professionals.The pharmacogenomics technology market is also likely to get bolstered technological advancements related to molecular diagnostics.
Besides, emerging economies need to think twice before affirming pharmacogenomics tests as initial as well as operating costs are high.
Governments herein do struggle with funding on this count.Download Sample Report @ https://www.millioninsights.com/industry-reports/pharmacogenomics-technology-market/request-sampleThe pharmacogenomics theranostics market is segmented by application, technology, end-user, and geography.
By application, the segmentation goes like cardiovascular disease, pain management, psychiatry, infectious diseases, oncology, and neurological disease.
By technology, the pharmacogenomics technology industry spans sequencing, polymerase chain reaction, mass spectrometry, microarray, and electrophoresis.
Global brain tumor diagnosis and therapeutics market size are anticipated to reach USD 773.1 million by 2025.
A brain tumor could be defined as an uncontrolled and abnormal proliferation of cells in the brain.
The factors that propel the growth of the brain tumor diagnosis and therapeutics industry include increasing requirement of treatment for symptoms related to brain metastasis, advancement in R technologies, increased occurrence of cancer that spread to the brain, discoveries in novel drug transfer to brain tumor cells, increasing the competence of diagnosis, increasing awareness among population.On the other hand, there are factors that could hamper the growth of the market including side effects associated with the chemotherapy and high cost of treatment.
Brain tumor diagnosis & therapeutics market are anticipated to expand at a significant CAGR of 8.1% in the upcoming period as the scope, product types, and its applications are increasing across the globe.Get Exclusive Free Sample Copy Of This Report @ https://www.millioninsights.com/industry-reports/brain-tumor-diagnosis-therapeutics-market/request-sampleBrain tumor diagnosis and therapeutics industry could be explored by product type, diagnostic type, treatment type, end user, and geography.
The industry could be explored by product type as Secondary Brain Tumor and Primary Brain Tumor (Gliomas, Meningioma, Pituitary Tumors, Astrocytoma’s and Others).
The market could be explored by the end user as Individual Pharmacies, Hospital Pharmacies, and Ambulatory Surgical Centers.North America accounted for the major market share of the brain tumor diagnosis and therapeutics in 2016 and will continue to lead in the forecast period.
Request a Sample PDF Copy of This Report @ https://www.millioninsights.com/industry-reports/europe-molecular-diagnostics-market/request-sample The key driving factors responsible for the growth of Europe Molecular Diagnostics market : The Europe molecular diagnostics industry on the source of Type of Application Pharmacogenomics, Neurological Disease, Microbiology, Cardiovascular Disease, Infectious Diseases.
The subdivision of Infectious Diseases held the biggest stake of the market, due to the greater occurrence of HIV.
The Europe molecular diagnostics market on the source of Type of Technology could span Transcription-mediated Amplification, Mass Spectrometry, Isothermal Nucleic Acid Amplification Technology [INAAT], PCR, [Multiplex PCR], Sequencing, Chips & Microarrays, and In Situ Hybridization.
It could be credited mostly to the growing use of molecular diagnostics in the arena of pharmacogenomics and the increasing practice of multiplex PCR skills.
The increasing demand for speedy analysis together with the readiness of freshly developed skill of Point of Care to observe the reactions of medicine, in patients through cardiac sicknesses, will subsidize in the direction of the progress of this subdivision.
The subdivision of reagents is likewise projected to boost at a dual digit CAGR above the prediction period.
Feb 24, 2021: The global Medical Marijuana Market size is expected to value at USD 55.8 billion by 2025.
The market is subject to witness a substantial growth due to the rise in number of medical applications such as pain management, appetite enhancement, and reducing eye pressure.
The Cannabis Sativa and Cannabis indica are naturally found in the western hemisphere and central & south Asian region respectively.
Additionally, growing competition in the market coupled with rising number of mergers and acquisitions in the medical marijuana market is anticipated to stimulate market development over the coming few years.
The technological advancements in the healthcare industry coupled with development of innovative drugs are some of the key factors for sustained market growth.Download sample Copy of This Report at: https://www.millioninsights.com/industry-reports/medical-marijuana-market/request-sampleIncreasing number of states with lawful legalizing medical marijuana in U.S. and high-end demand for cannabis in medical and recreational applications are predicted to favor market growth over the forecast period.
Therapeutic is one of the key application of the drug, thus propelling the market over the forecast period.Browse Full Report With TOC @ https://www.millioninsights.com/industry-reports/medical-marijuana-marketThe medical marijuana industry is broadly categorized into four major segments based on the application type such aschronic pain management segment, arthritis pain management segment, migraine pain management segment, cancer cell segment.
Global Angina Pectoris Drugs Market is estimated to reach USD 10.6 billion by 2022 owing to the rising number of patients suffering from angina pectoris and the probable acceptance of modern therapies like varespladib and Generx that are in late stage of clinical development.
If these modern therapies are approved, they are expected to contribute impressively to the growth of angina pectoris drugs industry since they will be sold at premium prices by manufacturing companies.
Angina Pectoris is mainly caused by growing prevalence of chronic diseases like high blood pressure, diabetes and obesity.
β-Blocker therapy is also used in asymptomatic patients with large areas of ischemia (level IIa C evidence) and in microvascular angina to recover effort-related angina symptoms.
A research revealed that chronic stable angina affects very less population in the western countries with an anticipated yearly risk of death and non-fatal myocardial infraction of comparatively less population.
The prominent players in angina pectoris drugs industry comprise Astellas Pharma, AstraZeneca PLC, Ark Therapeutics Group plc, Cardium Therapeutics, Cardeus Pharmaceuticals, CardioVascularBioTherapeutics (CVBT), HUYA Bioscience International LLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Korea Otsuka Pharmaceutical Co.Ltd, Pfizer, Inc., Baxalta US Inc., Gilead Sciences, Inc, Sanofi SA, and TSH Biopharm Corporation Limited.
11 February 2020 - Global Human Growth Hormone (HGH) Market is anticipated to witness an exponential growth in the forecast period.
Human growth hormone is mainly responsible for regeneration and growth among humans and stimulates cell reproduction.
Factors such as presence of a large pool of patients, technological advancements, demand for better-quality and cost-effective human growth hormones, increasing compliance for human growth hormone drugs and massive unexplored markets in the developing economies, such as China and India.Furthermore, advanced research and development services, and new drug developments by the key companies, increasing occurrences of human growth hormone deficiency diseases, and growing aged population are likely to propel the human growth hormone industry in the forthcoming period.
Human growth hormone (HGH) industry is anticipated to expand at a CAGR of 7.5% in the upcoming period as the scope, product types, and its applications are increasing across the globe.Human growth hormone market could be explored by route administration, application, distribution channel, and geography.
It is likely to witness substantial growth in the years to come.
The key factors that could be attributed to the growth of the market include the preference for the subcutaneous technique is rising as it leads to the important growth in development rates and low occurrence of antibody progress.
